Attendee search 

IMS offers magnetic antibodies and adaptor proteins to the life science community (research and bioprocessing) while further developing the technology platform for licensing and partnering opportunities in medicine (diagnostics and therapeutics).

PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.

IBML, through its associate companies, OctaPhillip Bioscience Managers Ltd and Union MedTech PLC, specialises in investment in life science and medical technology companies.

PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.

Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines, monoclonal antibodies, peptides, blood factors and fusion proteins

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease.

Haemostatix has developed a new class of peptide-based haemostat for the treatment of bleeding. The technology is based on a peptide that binds to the blood protein fibrinogen, inducing the rapid and targeted formation of clots.